{"id": "article-108794_0", "title": "Lemborexant -- Continuing Education Activity", "content": "Lemborexant is a medication used in the management and treatment of insomnia. It is in the dual orexin antagonist class of medications. This activity outlines the indications, actions, and contraindications for lemborexant as a valuable agent in managing insomnia. This activity will highlight the mechanism of action, adverse event profile, and other key factors such as dosing, monitoring, and drug interactions pertinent for interprofessional team members in the care of patients with insomnia and related conditions.", "contents": "Lemborexant -- Continuing Education Activity. Lemborexant is a medication used in the management and treatment of insomnia. It is in the dual orexin antagonist class of medications. This activity outlines the indications, actions, and contraindications for lemborexant as a valuable agent in managing insomnia. This activity will highlight the mechanism of action, adverse event profile, and other key factors such as dosing, monitoring, and drug interactions pertinent for interprofessional team members in the care of patients with insomnia and related conditions."}
{"id": "article-108794_1", "title": "Lemborexant -- Continuing Education Activity", "content": "Objectives: Summarize the management considerations for patients with insomnia. Describe the mechanism of action of lemborexant. Identify the most common adverse effects of lemborexant therapy. Review the importance of collaboration and communication amongst the interprofessional team to enhance the delivery of care for patients receiving lemborexant. Access free multiple choice questions on this topic.", "contents": "Lemborexant -- Continuing Education Activity. Objectives: Summarize the management considerations for patients with insomnia. Describe the mechanism of action of lemborexant. Identify the most common adverse effects of lemborexant therapy. Review the importance of collaboration and communication amongst the interprofessional team to enhance the delivery of care for patients receiving lemborexant. Access free multiple choice questions on this topic."}
{"id": "article-108794_2", "title": "Lemborexant -- Indications", "content": "Approved by the food and drug administration (FDA) in December of 2019, clinicians can use lemborexant to treat insomnia in adults. Additionally, lemborexant has been demonstrated to be safe for use in patients with mild obstructive sleep apnea (OSA). [1] There are no other currently approved indications\u00a0for which lemborexant may be used, although it\u00a0is currently used to treat irregular sleep-wake rhythm in patients with Alzheimer disease is currently under investigation. [2]", "contents": "Lemborexant -- Indications. Approved by the food and drug administration (FDA) in December of 2019, clinicians can use lemborexant to treat insomnia in adults. Additionally, lemborexant has been demonstrated to be safe for use in patients with mild obstructive sleep apnea (OSA). [1] There are no other currently approved indications\u00a0for which lemborexant may be used, although it\u00a0is currently used to treat irregular sleep-wake rhythm in patients with Alzheimer disease is currently under investigation. [2]"}
{"id": "article-108794_3", "title": "Lemborexant -- Indications", "content": "Lemborexant belongs to a class of drugs called dual receptor orexin antagonists (DORA), most of which are currently under evaluation in clinical trials, except for\u00a0suvorexant, which was FDA-approved for the treatment of primary insomnia in August of 2014. [3]", "contents": "Lemborexant -- Indications. Lemborexant belongs to a class of drugs called dual receptor orexin antagonists (DORA), most of which are currently under evaluation in clinical trials, except for\u00a0suvorexant, which was FDA-approved for the treatment of primary insomnia in August of 2014. [3]"}
{"id": "article-108794_4", "title": "Lemborexant -- Mechanism of Action", "content": "The two variants of the orexin molecule (orexin A and orexin B) play an important role in the human sleep-wake cycles. Orexin A acts nonselectively to both the orexin-1 receptor (OX1R) and orexin-2 receptors (OX2R), while Orexin B acts more selectively on OX2R. [4] Produced in the hypothalamus, the orexin peptides are released from\u00a0between 50,000\u00a0and 80,000 orexin-producing neurons in the human brain. Additionally, these orexin-producing neurons project to various other neurons, some of which\u00a0are noradrenergic, serotonergic, dopaminergic, and cholinergic, supporting potential mechanisms of sleep-wake maintenance. [5]", "contents": "Lemborexant -- Mechanism of Action. The two variants of the orexin molecule (orexin A and orexin B) play an important role in the human sleep-wake cycles. Orexin A acts nonselectively to both the orexin-1 receptor (OX1R) and orexin-2 receptors (OX2R), while Orexin B acts more selectively on OX2R. [4] Produced in the hypothalamus, the orexin peptides are released from\u00a0between 50,000\u00a0and 80,000 orexin-producing neurons in the human brain. Additionally, these orexin-producing neurons project to various other neurons, some of which\u00a0are noradrenergic, serotonergic, dopaminergic, and cholinergic, supporting potential mechanisms of sleep-wake maintenance. [5]"}
{"id": "article-108794_5", "title": "Lemborexant -- Mechanism of Action", "content": "The wakefulness effects of orexins agonizing OX1R and OX2R are widely accepted and consistently supported in animal models. Additionally, the inhibition of both the OX1R and OX2R has demonstrated sedative characteristics in both human and animal models.\u00a0Unlike most current medications used to treat insomnia, which act on the gamma-aminobutyric acid (GABA) receptor, lemborexant presents a unique mechanism of action. [6] [7] Lemborexant is considered a DORA, exerting its sedative effects by reversible competitive binding to, and thus inhibiting, the wakefulness effects of orexin on OX1R and OX2R, with a stronger affinity to OX2R.\u00a0The time to peak concentration blood concentration of the drug is approximately 1 to 3 hours. [7]", "contents": "Lemborexant -- Mechanism of Action. The wakefulness effects of orexins agonizing OX1R and OX2R are widely accepted and consistently supported in animal models. Additionally, the inhibition of both the OX1R and OX2R has demonstrated sedative characteristics in both human and animal models.\u00a0Unlike most current medications used to treat insomnia, which act on the gamma-aminobutyric acid (GABA) receptor, lemborexant presents a unique mechanism of action. [6] [7] Lemborexant is considered a DORA, exerting its sedative effects by reversible competitive binding to, and thus inhibiting, the wakefulness effects of orexin on OX1R and OX2R, with a stronger affinity to OX2R.\u00a0The time to peak concentration blood concentration of the drug is approximately 1 to 3 hours. [7]"}
{"id": "article-108794_6", "title": "Lemborexant -- Mechanism of Action", "content": "It has been proposed that taking advantage of this unique mechanism may come with fewer side effects than more commonly prescribed drugs to treat insomnia, such as benzodiazepines.\u00a0Current medications used to treat insomnia include benzodiazepines and \"z-drugs,\" which act on the GABA receptor, antihistamines that\u00a0disrupt the wakeful effects of\u00a0histamine, and trazodone, which exerts its effects on both the serotonergic system and histamine receptors. Benzodiazepines present with a high potential for misuse and physical and psychological dependence. [8] While still a relatively novel drug,\u00a0evidence suggests\u00a0lemborexant may be at least more effective with less potential for dependence than zolpidem, a non-benzodiazepine GABA receptor agonist.\u00a0Lemborexant effectively reduces sleep latency and increases maintenance compared to controls. Additionally, lemborexant appears to be more effective at improving sleep maintenance than zolpidem in patients with insomnia. [2] [9] Furthermore, there\u00a0is no evidence of withdrawal symptoms or associations with rebound insomnia upon withdrawal of either 5 mg or 10 mg\u00a0lemborexant\u00a0in both 30 day and 6-month trials. [2]", "contents": "Lemborexant -- Mechanism of Action. It has been proposed that taking advantage of this unique mechanism may come with fewer side effects than more commonly prescribed drugs to treat insomnia, such as benzodiazepines.\u00a0Current medications used to treat insomnia include benzodiazepines and \"z-drugs,\" which act on the GABA receptor, antihistamines that\u00a0disrupt the wakeful effects of\u00a0histamine, and trazodone, which exerts its effects on both the serotonergic system and histamine receptors. Benzodiazepines present with a high potential for misuse and physical and psychological dependence. [8] While still a relatively novel drug,\u00a0evidence suggests\u00a0lemborexant may be at least more effective with less potential for dependence than zolpidem, a non-benzodiazepine GABA receptor agonist.\u00a0Lemborexant effectively reduces sleep latency and increases maintenance compared to controls. Additionally, lemborexant appears to be more effective at improving sleep maintenance than zolpidem in patients with insomnia. [2] [9] Furthermore, there\u00a0is no evidence of withdrawal symptoms or associations with rebound insomnia upon withdrawal of either 5 mg or 10 mg\u00a0lemborexant\u00a0in both 30 day and 6-month trials. [2]"}
{"id": "article-108794_7", "title": "Lemborexant -- Administration -- Normal Dosing Recommendations", "content": "Lemborexant\u00a0is administered\u00a0orally in doses of either 5 mg or 10 mg immediately before bed. Patients should not use lemborexant if they\u00a0anticipate waking up before 7 hours after\u00a0taking the medication so as not to experience dangerous impairment while awake. The maximum recommended clinical dose of lemborexant should not exceed 10 mg. Additionally, taking this medication with food or before\u00a0eating may delay its onset of action. Lemborexant is not meant for use in combination with alcoholic beverages. Furthermore, there is no available research on lemborexant in\u00a0pediatric populations or pregnant or breastfeeding women.", "contents": "Lemborexant -- Administration -- Normal Dosing Recommendations. Lemborexant\u00a0is administered\u00a0orally in doses of either 5 mg or 10 mg immediately before bed. Patients should not use lemborexant if they\u00a0anticipate waking up before 7 hours after\u00a0taking the medication so as not to experience dangerous impairment while awake. The maximum recommended clinical dose of lemborexant should not exceed 10 mg. Additionally, taking this medication with food or before\u00a0eating may delay its onset of action. Lemborexant is not meant for use in combination with alcoholic beverages. Furthermore, there is no available research on lemborexant in\u00a0pediatric populations or pregnant or breastfeeding women."}
{"id": "article-108794_8", "title": "Lemborexant -- Adverse Effects", "content": "Adverse effects of lemborexant include: Somnolence Drowsiness CNS depressant effects/daytime impairment Sleep paralysis Hypnagogic/hypnopompic hallucinations Cataplexy-like symptoms Complex sleep behaviors Worsening of depression/suicidal ideation", "contents": "Lemborexant -- Adverse Effects. Adverse effects of lemborexant include: Somnolence Drowsiness CNS depressant effects/daytime impairment Sleep paralysis Hypnagogic/hypnopompic hallucinations Cataplexy-like symptoms Complex sleep behaviors Worsening of depression/suicidal ideation"}
{"id": "article-108794_9", "title": "Lemborexant -- Contraindications -- Absolute Contraindication", "content": "Narcolepsy is an absolute contraindication of lemborexant.", "contents": "Lemborexant -- Contraindications -- Absolute Contraindication. Narcolepsy is an absolute contraindication of lemborexant."}
{"id": "article-108794_10", "title": "Lemborexant -- Contraindications -- Drug Interactions or Dosing Modifications", "content": "Avoid:\u00a0Avoid taking lemborexant with strong\u00a0(itraconazole and clarithromycin) or moderate\u00a0(fluconazole and verapamil) CYP3A inhibitors, which may increase the adverse effects of lemborexant. Avoid: Avoid taking lemborexant with strong (rifampin, carbamazepine, and St. John\u2019s wort) or moderate (bosentan, efavirenz, etravirine, and modafinil) CYP3A inducers, which may reduce the effectiveness of lemborexant. Use with caution:\u00a0Do not use a dose of greater than 5 mg\u00a0when co-administering with weak CYP3A inhibitors to avoid adverse effects. Use with caution:\u00a0at doses greater than 5mg in patients over the age of 65. Mild hepatic impairment (Child-Pugh class A):\u00a0May experience increased somnolence, but there is no recommended dose adjustment. Moderate hepatic impairment (Child-Pugh class B):\u00a0A nightly dose greater than 5 mg is not recommended in patients with moderate hepatic impairment.", "contents": "Lemborexant -- Contraindications -- Drug Interactions or Dosing Modifications. Avoid:\u00a0Avoid taking lemborexant with strong\u00a0(itraconazole and clarithromycin) or moderate\u00a0(fluconazole and verapamil) CYP3A inhibitors, which may increase the adverse effects of lemborexant. Avoid: Avoid taking lemborexant with strong (rifampin, carbamazepine, and St. John\u2019s wort) or moderate (bosentan, efavirenz, etravirine, and modafinil) CYP3A inducers, which may reduce the effectiveness of lemborexant. Use with caution:\u00a0Do not use a dose of greater than 5 mg\u00a0when co-administering with weak CYP3A inhibitors to avoid adverse effects. Use with caution:\u00a0at doses greater than 5mg in patients over the age of 65. Mild hepatic impairment (Child-Pugh class A):\u00a0May experience increased somnolence, but there is no recommended dose adjustment. Moderate hepatic impairment (Child-Pugh class B):\u00a0A nightly dose greater than 5 mg is not recommended in patients with moderate hepatic impairment."}
{"id": "article-108794_11", "title": "Lemborexant -- Contraindications", "content": "Severe hepatic impairment (Child-Pugh class C):\u00a0Researchers have not studied lemborexant in severe hepatic impairment, and therefore the current recommendation for such patients is to avoid using the drug.", "contents": "Lemborexant -- Contraindications. Severe hepatic impairment (Child-Pugh class C):\u00a0Researchers have not studied lemborexant in severe hepatic impairment, and therefore the current recommendation for such patients is to avoid using the drug."}
{"id": "article-108794_12", "title": "Lemborexant -- Monitoring", "content": "The elimination half-life of lemborexant was 17 hours and 19 hours in 5 mg and 10 mg doses, respectively. Age, body mass index (BMI), race, or sex have no impact on the elimination half-life of the drug. There are no dosage adjustment recommendations in patients with mild, moderate, or severe renal impairment, although patients with severe renal illness may experience excessive somnolence.", "contents": "Lemborexant -- Monitoring. The elimination half-life of lemborexant was 17 hours and 19 hours in 5 mg and 10 mg doses, respectively. Age, body mass index (BMI), race, or sex have no impact on the elimination half-life of the drug. There are no dosage adjustment recommendations in patients with mild, moderate, or severe renal impairment, although patients with severe renal illness may experience excessive somnolence."}
{"id": "article-108794_13", "title": "Lemborexant -- Monitoring", "content": "Compared\u00a0to the more popular hypnotic drug zolpidem,\u00a0lemborexant appears to\u00a0exhibit far less potential for misuse. Patients who use it do not appear to be at risk for developing dependence or withdrawal symptoms. This characteristic may indicate that lemborexant may be a safer option for patients with a history of addiction or drug abuse. Nonetheless, lemborexant is a Schedule IV-controlled substance with sedative properties and should be used and prescribed with caution. Further research is warranted to investigate the abuse potential for lemborexant. Furthermore, lemborexant should be compared to commonly prescribed GABA agonists other than zolpidem, particularly hypnotic benzodiazepines, as current evidence suggests it may be a safer option.", "contents": "Lemborexant -- Monitoring. Compared\u00a0to the more popular hypnotic drug zolpidem,\u00a0lemborexant appears to\u00a0exhibit far less potential for misuse. Patients who use it do not appear to be at risk for developing dependence or withdrawal symptoms. This characteristic may indicate that lemborexant may be a safer option for patients with a history of addiction or drug abuse. Nonetheless, lemborexant is a Schedule IV-controlled substance with sedative properties and should be used and prescribed with caution. Further research is warranted to investigate the abuse potential for lemborexant. Furthermore, lemborexant should be compared to commonly prescribed GABA agonists other than zolpidem, particularly hypnotic benzodiazepines, as current evidence suggests it may be a safer option."}
{"id": "article-108794_14", "title": "Lemborexant -- Toxicity", "content": "Clinical evidence to support toxic doses of lemborexant in humans is scarce. In at least one clinical study, 7.5 times the recommended dose of lemborexant was given to healthy human subjects resulting in dose-dependent increases of somnolence frequency, providing little information regarding toxicity. There is no specific antidote to lemborexant overdose. In the case of a suspected overdose, the protocol of any drug overdose should be followed, with close monitoring from a medical professional.", "contents": "Lemborexant -- Toxicity. Clinical evidence to support toxic doses of lemborexant in humans is scarce. In at least one clinical study, 7.5 times the recommended dose of lemborexant was given to healthy human subjects resulting in dose-dependent increases of somnolence frequency, providing little information regarding toxicity. There is no specific antidote to lemborexant overdose. In the case of a suspected overdose, the protocol of any drug overdose should be followed, with close monitoring from a medical professional."}
{"id": "article-108794_15", "title": "Lemborexant -- Enhancing Healthcare Team Outcomes", "content": "Managing insomnia with lemborexant requires\u00a0communication between interprofessional healthcare team members,\u00a0including clinicians, pharmacists, nurses, and other healthcare assistants. Patients should be aware of the possible risks of using lemborexant, especially those with pre-existing conditions such as drug abuse disorder or hepatic impairment. While lemborexant appears to be a safe option for treating insomnia in adults, it is a schedule IV-controlled substance and should be treated by patients and healthcare providers as such. Additionally, further randomized controlled trials are warranted due to the novelty and apparent advantages of lemborexant compared to current treatments. Lemborexant utilizes\u00a0a novel mechanism of action, potentially\u00a0presenting a superior safety profile for adults receiving pharmaceutical treatment for insomnia. [7] [10] [2] [Level 1]", "contents": "Lemborexant -- Enhancing Healthcare Team Outcomes. Managing insomnia with lemborexant requires\u00a0communication between interprofessional healthcare team members,\u00a0including clinicians, pharmacists, nurses, and other healthcare assistants. Patients should be aware of the possible risks of using lemborexant, especially those with pre-existing conditions such as drug abuse disorder or hepatic impairment. While lemborexant appears to be a safe option for treating insomnia in adults, it is a schedule IV-controlled substance and should be treated by patients and healthcare providers as such. Additionally, further randomized controlled trials are warranted due to the novelty and apparent advantages of lemborexant compared to current treatments. Lemborexant utilizes\u00a0a novel mechanism of action, potentially\u00a0presenting a superior safety profile for adults receiving pharmaceutical treatment for insomnia. [7] [10] [2] [Level 1]"}
{"id": "article-108794_16", "title": "Lemborexant -- Enhancing Healthcare Team Outcomes", "content": "Patient education and post-prescribing monitoring with lemborexant are best accomplished with an interprofessional healthcare team exercising collaborative activity and open information sharing to drive optimal patient outcomes. [Level 5]", "contents": "Lemborexant -- Enhancing Healthcare Team Outcomes. Patient education and post-prescribing monitoring with lemborexant are best accomplished with an interprofessional healthcare team exercising collaborative activity and open information sharing to drive optimal patient outcomes. [Level 5]"}
{"id": "article-108794_17", "title": "Lemborexant -- Review Questions", "content": "Access free multiple choice questions on this topic. Comment on this article.", "contents": "Lemborexant -- Review Questions. Access free multiple choice questions on this topic. Comment on this article."}